Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Orlistat

Xenical

Stage Approved

Sponsor Empros Pharma AB

Route oral

Class Lipase inhibitor

Mechanism lipase inhibitor

Sources

registry, as of 2020-04-07Stale

https://clinicaltrials.gov/study/NCT01755676

Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults. Overall status COMPLETED. Phases PHASE3. Lead sponsor EMS. Enrollment 638. Conditions Obesity. The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.

ClinicalTrials.gov NCT01755676 protocol and results modules

registry, as of 2022-02-03Stale

https://clinicaltrials.gov/study/NCT02432209

Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility. Overall status COMPLETED. Phases PHASE3. Lead sponsor Yale University. Enrollment 379. Conditions Infertility, Female. A two-arm, multicenter, prospective, randomized clinical trial of a lifestyle modification program with tracked increased physical activity and weight loss (intensive) compared to recommendations to tracking of increased physical activity alone with weight maintenance (standard) deaths Intensive Lifestyle Mod. Intervention 0 diarrhea Intensive Lifestyle Mod. Intervention 35 deaths Standard Lifestyle Intervention 0 diarrhea Standard Lifestyle Intervention 9

ClinicalTrials.gov NCT02432209 protocol and results modules

registry, as of 2016-04-05Stale

https://clinicaltrials.gov/study/NCT00940628

A Study of Xenical (Orlistat) in Overweight and Obese Adolescents. Overall status COMPLETED. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 60. Conditions Obesity. This 2 arm study will assess the effect of Xenical on body mass index (BMI)in obese or overweight adolescents. Patients will be randomised into one of 2 groups; both groups will undergo a regimen of mildly hypocaloric diet and physical exercise, but one group will also receive Xe

ClinicalTrials.gov NCT00940628 protocol and results modules

registry, as of 2011-02-23Stale

https://clinicaltrials.gov/study/NCT01047657

Effects of Weight Loss in Obese Difficult-to-treat Asthmatics. Overall status COMPLETED. Phases PHASE3. Lead sponsor University of Sao Paulo General Hospital. Enrollment 33. Conditions Asthma; Obesity; Weight Loss. Sixty percent of patients with difficult to control asthma seen in our outpatient clinic are obese. The impact of weight reduction in this subpopulation of asthmatics has not been studied. Our aim is to evaluate the impact of weight reduction on asthma control of these patients.

ClinicalTrials.gov NCT01047657 protocol and results modules

registry, as of 2006-08-29Stale

https://clinicaltrials.gov/study/NCT00156897

Efficacy and Safety of ATL-962 in Obese Diabetics. Overall status COMPLETED. Phases PHASE2. Lead sponsor Alizyme. Enrollment 600. Conditions Non-Insulin-Dependent Diabetes Mellitus; Obesity. The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients

ClinicalTrials.gov NCT00156897 protocol and results modules

registry, as of 2018-05-09Stale

https://clinicaltrials.gov/study/NCT01126970

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shionogi. Enrollment 486. Conditions Obesity. To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the steady-state trough concentrations of velneperit (S-2367),

ClinicalTrials.gov NCT01126970 protocol and results modules

registry, as of 2024-02-20Stale

https://clinicaltrials.gov/study/NCT05934110

Study Exploring the Supportive Effect of Acarbose in Weight Management. Overall status UNKNOWN. Phases PHASE2. Lead sponsor Empros Pharma AB. Enrollment 320. Conditions Overweight or Obesity. This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination product with modified release (MR) orlistat, orlistat

ClinicalTrials.gov NCT05934110 protocol and results modules

registry, as of 2012-12-18Stale

https://clinicaltrials.gov/study/NCT00001723

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases. Overall status COMPLETED. Phases PHASE2. Lead sponsor Jack Yanovski. Enrollment 200. Conditions Diabetes Mellitus; Hypertension; Metabolic Disease; Obesity; Sleep Apnea Syndrome. Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals diarrhea Orlistat 21 nausea Orlistat 10 vomiting Orlistat 7 diarrhea Placebo 8 nausea Placebo 9 vomiting Placebo 7

ClinicalTrials.gov NCT00001723 protocol and results modules

registry, as of 2022-04-04Stale

https://clinicaltrials.gov/study/NCT04521751

A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary). Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Empros Pharma AB. Enrollment 156. Conditions Overweight or Obesity. This study is a proof of concept study to demonstrate that EMP16-02, a fixed dose combination (FDC) of orlistat and acarbose in an oral multiple-unit modified release (MR) formulation leads to a clinically relevant decrease in body weight. The study aims to evaluate the efficacy,

ClinicalTrials.gov NCT04521751 protocol and results modules

registry, as of 2018-08-17Stale

https://clinicaltrials.gov/study/NCT02069197

Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea. Overall status UNKNOWN. Phases PHASE2. Lead sponsor Mid-Atlantic Epilepsy and Sleep Center, LLC. Enrollment 150. Conditions Obesity; Diabetes; Obstructive Sleep Apnea. The purpose of the study is to evaluate the efficacy and safety of ketogenic diet (KD) treatment of (i) obesity, (ii) type 2 diabetes mellitus and (iii) obstructive sleep apnea (OSA) in patients with obesity and Type 2 DM and in patients with obesity and/or OSA. This will be a ra

ClinicalTrials.gov NCT02069197 protocol and results modules

registry, as of 2026-03-12Stale

https://clinicaltrials.gov/study/NCT01351753

Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity. Overall status TERMINATED. Phases PHASE2. Lead sponsor University of Iowa. Enrollment 128. Conditions Obesity; Metabolic Syndrome X. Obesity is common (\>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions. Partly it is due to the limited efficacy and safety problems of existi

ClinicalTrials.gov NCT01351753 protocol and results modules

registry, as of 2021-04-01Stale

https://clinicaltrials.gov/study/NCT01003483

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor Yazd Research & Clinical Center for Infertility. Enrollment 80. Conditions Obesity. The purpose of this study is to compare the influence of Orlistat and Metformin on obesity treatment in obese PCOS women.

ClinicalTrials.gov NCT01003483 protocol and results modules

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6240792b-9224-2d10-e053-2a91aa0a2c3e

t identified an increased risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. However, weight loss offers no benefit to a pregnant patient and may result in a small for gestational age infant. When a pregnancy is recognized, advise the pregnant patient of the

DailyMed xenical, indication text

publication, as of 2026-10-12Stale

https://pubmed.ncbi.nlm.nih.gov/42855032/

Digestive lipases as therapeutic targets in obesity: From Orlistat to next-generation inhibitors. Obesity remains a global pandemic and a major driver of metabolic diseases, with current pharmacotherapies often limited by modest efficacy, systemic side effects, high costs, an

PMID 42855032

Studies

Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults

Registry NCT01755676

Phase Phase 3

Status Completed

Enrollment 638

Study completion 2017-12-21

Orlistat 60 mg

Dose 60 mg

Comparator placebo

Population Obesity

Placebo

Population Obesity

FIT-PLESE

Registry NCT02432209

Phase Phase 3

Status Completed

Enrollment 379

Primary completion 2019-11-30

Intensive Lifestyle Mod. Intervention

Comparator placebo

Population Infertility, Female

deaths

participants with diarrhea, 35 participantsStale

Standard Lifestyle Intervention

Population Infertility, Female

deaths

participants with diarrhea, 9 participantsStale

A Study of Xenical (Orlistat) in Overweight and Obese Adolescents

Registry NCT00940628

Phase Phase 3

Status Completed

Enrollment 60

1

Population Obesity

2

Population Obesity

Effects of Weight Loss in Obese Difficult-to-treat Asthmatics

Registry NCT01047657

Phase Phase 3

Status Completed

Enrollment 33

weight loss

Population Asthma; Obesity; Weight Loss

Control

Population Asthma; Obesity; Weight Loss

Efficacy and Safety of ATL-962 in Obese Diabetics

Registry NCT00156897

Phase Phase 2

Status Completed

Enrollment 600

Registry arm not named

Population Non-Insulin-Dependent Diabetes Mellitus; Obesity

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet

Registry NCT01126970

Phase Phase 2

Status Completed

Enrollment 486

Placebos.

Population Obesity

Velneperit 400 mg

Dose 400 mg

Comparator placebo

Population Obesity

Orlistat 120 mg

Dose 120 mg

Comparator placebo

Population Obesity

Velneperit 400 mg + Orlistat 120 mg

Dose 120 mg

Comparator placebo

Population Obesity

Study Exploring the Supportive Effect of Acarbose in Weight Management

Registry NCT05934110

EudraCT 2022-003320-40

Phase Phase 2

Enrollment 320

Start 2023-04-18

Primary completion 2023-11-21

Study completion 2024-03-15

EMP16-120/40

Comparator placebo

Population Overweight or Obesity

MR orlistat

Comparator placebo

Population Overweight or Obesity

Conventional orlistat

Comparator placebo

Population Overweight or Obesity

EMP16-60/20

Comparator placebo

Population Overweight or Obesity

Placebo

Population Overweight or Obesity

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

Registry NCT00001723

Phase Phase 2

Status Completed

Enrollment 200

Placebo

Regimen once monthly

Weeks 12

Population Diabetes Mellitus; Hypertension; Metabolic Disease; Obesity; Sleep Apnea Syndrome

participants with diarrhea, 8 participantsStale

participants with nausea, 9 participantsStale

participants with vomiting, 7 participantsStale

Orlistat

Regimen once monthly

Weeks 12

Comparator placebo

Population Diabetes Mellitus; Hypertension; Metabolic Disease; Obesity; Sleep Apnea Syndrome

participants with diarrhea, 21 participantsStale

participants with nausea, 10 participantsStale

participants with vomiting, 7 participantsStale

A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)

Registry NCT04521751

Phase Phase 1/2

Status Completed

Enrollment 156

Start 2020-05-07

Primary completion 2021-08-30

Study completion 2021-08-30

EMP16-02 120 mg orlistat/40 mg acarbose

Dose 40 mg

Regimen daily

Weeks 26

Comparator placebo

Population Overweight or Obesity

EMP16-02 150 mg orlistat/50 mg acarbose

Dose 50 mg

Regimen daily

Weeks 26

Comparator placebo

Population Overweight or Obesity

Placebo

Regimen daily

Weeks 26

Population Overweight or Obesity

KGDobesity

Registry NCT02069197

Phase Phase 2

Enrollment 150

Ketogenic diet, lifestyle counseling

Population Obesity; Diabetes; Obstructive Sleep Apnea

Orlistat, Lifestyle counseling

Population Obesity; Diabetes; Obstructive Sleep Apnea

Standartized diet, Lifestyle counseling

Population Obesity; Diabetes; Obstructive Sleep Apnea

REVIVE

Registry NCT01351753

Phase Phase 2

Status Terminated

Enrollment 128

Primary completion 2014-01-09

Study completion 2014-01-09

Metformin

Comparator placebo

Population Obesity; Metabolic Syndrome X

Metformin + Orlistat

Comparator placebo

Population Obesity; Metabolic Syndrome X

Metformin + Topiramate

Comparator placebo

Population Obesity; Metabolic Syndrome X

Topiramate

Comparator placebo

Population Obesity; Metabolic Syndrome X

Metformin + Topiramate + Orlistat

Comparator placebo

Population Obesity; Metabolic Syndrome X

Placebo

Population Obesity; Metabolic Syndrome X

Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients

Registry NCT01003483

Phase Phase 2

Status Completed

Enrollment 80

Start 2008-12-01

Orlistat

Regimen daily

Population Obesity

Metformin

Regimen once daily

Population Obesity